Form DEFA14A WILLIS LEASE FINANCE
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
Willis Lease Finance Corporation
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
Willis Lease Finance Corporation
4700 Lyons Technology Parkway
Coconut Creek, Florida 33073
IMPORTANT NOTICE REGARDING THE 2026 ANNUAL
MEETING OF STOCKHOLDERS
The following notice of annual meeting was delivered to registered stockholders of Willis Lease Finance Corporation (the “Company”) on June 2, 2026 in connection with the 2026 annual meeting of the Company’s stockholders that was convened May 26, 2026 and adjourned to Tuesday, June 23, 2026, at 10:00 A.M. eastern time.
THE FOLLOWING NOTICE SUPPLEMENTS AND SHOULD BE READ IN
CONJUNCTION WITH THE PROXY STATEMENT
June 2, 2026
Notice of Annual Meeting
To our stockholders:
As announced at the 2026 Annual Meeting of Stockholders (as adjourned and reconvened from time to time, the “Annual Meeting”) of Willis Lease Finance Corporation (the “Company”) held on May 26, 2026, the Annual Meeting with respect to Proposal 2 was adjourned until Tuesday, June 23, 2026, at 10:00 a.m. eastern time.
“Proposal 2” describes the proposed stockholder approval to amend the Company’s certificate of incorporation to effect a three-for-one forward stock split and increase the number of authorized shares of common stock and preferred stock of the Company. Proposal 2 (and the other proposals presented at the Annual Meeting) are described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 24, 2026 (as amended and supplemented from time to time, the “Proxy Statement”).
The reconvened Annual Meeting will be held virtually via live webcast. Stockholders who have not yet registered to attend the Annual Meeting may do so prior to the reconvened Annual Meeting at www.proxydocs.com/WLFC.
The record date for determining stockholders eligible to vote at the Annual Meeting will remain the close of business on April 6, 2026. Valid proxies submitted prior to the Annual Meeting on May 26, 2026 with respect to Proposal 2 will continue to be valid for the reconvened Annual Meeting on June 23, 2026, unless properly changed or revoked prior to being exercised at the reconvened Annual Meeting on June 23, 2026.
You are advised to read the Proxy Statement in its entirety because it contains important information about Proposal 2. The Board of Directors recommends that you vote FOR Proposal 2. If you have already voted FOR Proposal 2 and do not want to change your vote, no further action is required at this time.
Thank you for your support.
Sincerely,
Z. Clifton Dameron IV
Senior Vice President,
General Counsel and
Corporate Secretary
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be Held on June 23, 2026
The Proxy Statements and various supplements thereto are available at www.proxydocs.com/WLFC
|
If you have any questions, or need assistance in voting your shares, please call our proxy solicitor:
INNISFREE M&A INCORPORATED +1 (877) 825-8772 (toll-free from the U.S. and Canada) or +1 (412) 232-3651 (from other countries)
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E
- OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
- Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share